Page 1

INTERIM REPORT 9M 2021 January - September 2021 Oncoral - entering clinical collaboration SIGNIFICANT EVENTS IN Q3 2021 ■ Clinical collaboration agreement with Taiho Oncology Inc. for the development of Oncoral in combination with LONSURFⓇ ■ Abstract for Orviglance comparison study to gadolinium accepted as an oral paper presentation at the world's largest radiology conference RSNA ■ FDA conditionally accepted Orviglance® as the brand name for Mangoral Guidance for expected recruitment completion to the SPARLE trial was extended to H1 2022 ( previously H2 2021 ) SIGNIFICANT EVENTS AFTER THE PERIOD ■ Food Effect Study with Orviglance successfully completed KEY RATIOS GROUP " The agreement with Taiho Oncology shows the potential for Oncoral to be part of a new all - oral treatment regimen for gastric cancer Q3 ( Jul - Sep ) 2021 OPERATING RESULT ( SEKm ) -32.7 2020 -0.82 EARNINGS PER SHARE ( SEK ) -16.3 291.0 -0.51 CASH FLOW FROM OPERATIONS ( SEKM ) -30.7 -18.9 ASCELIA PHARMA Advancing Orphan Oncology 220.7 9M ( Jan - Sep ) 2021 -98.8 -2.80 LIQUID ASSETS INCL . MARKETABLE SECURITIES ( SEKM ) -84.3 291.0 2020 -65.5 -2.47 -58.0 220.7